BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T020428
CREATED:20250812T105107Z
LAST-MODIFIED:20250812T105107Z
UID:41720-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:9th Complement-Based Drug Development Summit
DESCRIPTION:Diving Into the Complement Cascade to Explore Intervention Points\, Harnessing Biomarker Strategies to Identify Optimal Patient Populations\, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. \nSo far\, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis\, Annexon Biosciences and Omeros\, are making significant clinical progress in PNH\, AMD\, IgAN and C3G\, whilst key academics such as Michael Holers\, Michael Brenner\, and Brahm Segal continue to make discoveries in complement imaging\, novel pathways\, and new therapeutics areas such as oncology and transplantation. \nThe Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development\, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront. \nJoin us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development\, from basic biology to diagnostics and clinical development. \nParticipate in three dedicated workshops for active discussion on key topics including the intracellular complement system\, bispecific complement mediators\, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets. \nThis comprehensive program spans a broad spectrum of renal\, ophthalmic\, neurological\, and haematological indications\, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations. \nJoin 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.
URL:http://www.pharmajournalist.com/event/9th-complement-based-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T020428
CREATED:20250820T123645Z
LAST-MODIFIED:20250820T123645Z
UID:41743-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:7th Cell Therapy Analytical Development Summit
DESCRIPTION:Recognized as the industry’s leading forum for cell therapy analytical\, quality control\, assay\, and CMC professionals\, the 7th Cell Therapy Analytical Development Summit\, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda\, Arsenal Bio\, Bayer\, Genentech\, Adicet Bio\, Quell Therapeutics\, and the National Institute of Health\, as they share proven strategies\, innovative technologies and best-in-class approaches to enhance your product safety and quality\, ahead of regulatory approval. \nNow combined with the previously separate\, Cell Therapy Potency Assay Summit\, this meeting provides you with an even more comprehensive agenda\, covering the full landscape of analytical development\, across early- and late-stage assay development tracks. Join us this December to fast-track the next era of safe\, potent and robust cell therapies to market! \nFor more information\, please visit https://ter.li/9uagdj
URL:http://www.pharmajournalist.com/event/7th-cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250812T104500Z
LAST-MODIFIED:20250812T104500Z
UID:41714-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:8th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs\, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative\, cancer and rare disorders. In 2025 alone\, the field has seen major collaborations\, including Wayfinder Biosciences with Daiichi Sankyo\, Ono Pharmaceutical with Reborna Biosciences\, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence. \nNow in its 8th year\, the RNA-Targeted Drug Discovery & Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators\, covalent drugs\, proximity inducers and direct RNA binders.\nJoin 25+ world-class speakers from leaders like PTC Therapeutics\, ReviR Therapeutics\, Remix Therapeutics\, Rgenta Therapeutics\, Arrakis Therapeutics and more this December to gain the connections\, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond. \nStep into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data\, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA. \nThis year\, join 80+ experts in RNA biology\, drug discovery\, medicinal chemistry\, and structural biology to gain the latest data on visualizing dynamic RNA structures\, identifying functional binders\, improving selectivity\, enhancing delivery stability and achieving oral bioavailability. \nWhether you’re focused on RNA splice modulators\, covalent binders\, proximity inducing drugs\, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic. \nConnect with your global community at the world’s only meeting for RNA-targeted drug experts. \nTo know more visit: https://ter.li/rcvdor
URL:http://www.pharmajournalist.com/event/8th-rna-targeted-drug-discovery-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250820T122909Z
LAST-MODIFIED:20250820T122909Z
UID:41738-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Innovation in Obesity Therapeutics Summit
DESCRIPTION:The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly and Boehringer Ingelheim\, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. \nDon’t miss this pivotal opportunity to network with 60+ experts in the field of obesity\, forge crucial collaborations\, and be part of the solution. \nFind out more here: https://ter.li/vnapww
URL:http://www.pharmajournalist.com/event/2nd-innovation-in-obesity-therapeutics-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250829T120338Z
LAST-MODIFIED:20250829T120338Z
UID:41820-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nFind out more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T020428
CREATED:20250905T112712Z
LAST-MODIFIED:20250905T112817Z
UID:41881-1764633600-1764806399@www.pharmajournalist.com
SUMMARY:Designing the AI-Enabled Biopharma Workforce Summit
DESCRIPTION:The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences\nMost roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself\, in what jobs\, with what skills\, and across what proportion of our workforces is not yet fully clear. \nWhat is clear\, though\, is that the future depends on what we do now. The most forward-thinking companies already know that innovation doesn’t just happen at the bench\, it also takes place company-wide in working out what needs to be done\, how\, and by whom. \nThey are building future workforce capability faster by reassessing the needs of each department and fundamentally rethinking what work is best done by people versus what can be automated with technology. For the first time\, this forum will shine a light on how this is done. \nTaking part will help you approach organizational design with a new perspective which is skills centric\, rather than job centric and allow you to walk away with a new skills taxonomy that will help you deliver more productivity and more innovation from fewer people in less time. \nDownload the Agenda
URL:http://www.pharmajournalist.com/event/designing-the-ai-enabled-biopharma-workforce-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250905T114029Z
LAST-MODIFIED:20250905T114054Z
UID:41892-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:5th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Navigate New FDA Leadership\, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical\, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market \nWith major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nLearn more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/5th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250919T105408Z
LAST-MODIFIED:20250919T105408Z
UID:41976-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:6th Gene Therapy for Ophthalmic Disorders Summit
DESCRIPTION:The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh\, North Carolina\, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions\, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need. \nMomentum in 2025 is stronger than ever. Kriya Therapeutics is advancing its preclinical pipeline\, Opus Genetics and SpliceBio are progressing into early trials\, while Ocugen\, 4D Molecular Therapeutics\, and AbbVie are racing toward BLA approval. Against this backdrop of progress\, challenges around endpoint selection\, funding strategies\, and safe delivery methods remain at the forefront. The summit provides a unique platform to tackle these issues head-on and drive forward meaningful breakthroughs. \nAttendees will gain access to exclusive data and insights\, including preclinical updates from Opus Genetics\, Coave Therapeutics\, and Axovia Therapeutics\, alongside pivotal 2025 clinical progress shared by Ocugen\, Adverum Biotechnologies\, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski\, Partner & Head of Research at Luma Group\, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches. \nAdditional sessions will spotlight patient-led regulatory engagement\, comparative analyses of delivery approaches\, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline. \nFeaturing 18+ senior expert speakers\, 3+ hours of clinical data\, 2+ hours of preclinical research\, and 6+ hours of networking opportunities\, the summit unites biopharma leaders\, investors\, and innovators to accelerate progress from IND through to late-stage clinical development. \nJoin us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain\, uncover the next wave of breakthroughs beyond Luxturna\, and ensure your therapy reaches patients faster. \n View the full event program on our website here: https://ter.li/0duhtz
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-for-ophthalmic-disorders-summit/
LOCATION:DoubleTree by Hilton Raleigh Midtown\, 2805 Highwoods Blvd\, Raleigh\, NC\, 27604\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250805T115734Z
LAST-MODIFIED:20250805T120701Z
UID:41643-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond\, the field has grown from strength to strength. With a surge of billion-dollar investments\, the release of new groundbreaking data\, and recent real-world clinical progression\, the autoimmune cell therapy field is poised for clinical and commercial success. \nThe 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia\, PA) returns at a pivotal time\, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers\, with expertise spanning CAR-T\, Treg\, in vivo and NK cell therapies\, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications. \nAccess Your Brand-New 2025 Agenda Copy! \nLearn directly from industry titans including Cabaletta Bio\, Kyverna Therapeutics\, Umoja Biopharma\, Cartesian Therapeutics\, Century Therapeutics\, Artiva Biotherapeutics and Novartis\, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success. \nWhether you are preparing for your first clinical trials\, or making the transition into later phases\, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you. \n\nPreclinical & Translational: Address challenges in antigen selection\, delve into autologous and allogeneic translational strategies\, and discuss alternatives to B-cell depletion\, to bring the next wave of therapies to the clinic.\nClinical: Unpack trial design\, evaluate long-term clinical outcomes\, share regulatory strategies\, and learn how to operationalize studies for broader patient access.\n\nWith cell therapy companies increasingly targeting autoimmune diseases\, and autoimmune companies continuing to embrace cellular approaches\, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality. \nEvent Guide | Register | Learn More
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251203
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T020428
CREATED:20250827T112407Z
LAST-MODIFIED:20250827T112407Z
UID:41782-1764720000-1764892799@www.pharmajournalist.com
SUMMARY:14th Tumour Models Summit London
DESCRIPTION:With the European oncology market increasingly focused on emerging modalities\, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody\, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions\, there has never been a more important year to stay up to date with the latest innovations in tumour modelling. \nAs the longest-standing forum from the world-renowned Tumour Models event series\, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma\, biotech\, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic. \nDownload the event guide for full details: https://ter.li/hsztzb
URL:http://www.pharmajournalist.com/event/14th-tumour-models-summit-london/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251208
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T020428
CREATED:20251003T095343Z
LAST-MODIFIED:20251003T095343Z
UID:42107-1765152000-1765411199@www.pharmajournalist.com
SUMMARY:LEAP TD: Life Sciences
DESCRIPTION:As biopharma organizations decrease their budgets and move away from a recruitment-centric approach\, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. \nThis December in Boston\, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support scientific progress and organizational resilience. \nJoin 60+ senior L&D\, HR\, and training leaders from top biotech and pharma organizations to transform your L&D strategy to develop and retain a highly skilled\, agile scientific while building a resilient leadership pipeline to accelerate innovative research and development. This is your opportunity to rethink how learning\, leadership\, and a renewed focus on strategic workforce planning can drive measurable business impact\, commercial\, and scientific success. \nHow will attending help you? \n\nAccelerate workforce readinessby designing learning interventions that evolve with AI\, automation\, and cutting-edge scientific advancements\nBridge critical talent gapsthrough career pathways that upskill teams in biomanufacturing\, regulatory science\, and data fluency\nEmpower future-ready leaderswith the capabilities to navigate complexity\, drive innovation\, and lead transformational change\n\nAttending companies include Bristol Myers Squibb\, Vertex Pharma\, Biogen\, Labcorp\, Kyowa Kirin\, Arcus Biosciences\, Takeda\, and many other leading biotech and pharma organizations. \nThrough focused case studies and peer-led discussions\, attendees will uncover how leading teams are embedding development into the daily realities of regulated environments\, enabling leadership at every level\, and designing learning experiences that reflect the complexity of life sciences work. Whether you’re building scalable mentorship programs\, rethinking onboarding for scientific roles\, or aligning development with compliance and innovation goals\, this is your opportunity to connect with peers facing similar challenges and leave with strategies that drive measurable impact. \nThis is not another L&D expo. It’s a strategic\, high-level forum where talent development\, training\, and L&D leaders working in life sciences come together to discuss their talent development challenges and uncover new strategies in a collaborative environment. \nTo learn more about the event and find out whether this is the event that you need to take your biopharma workforce to the next level\, view the event brochure here: https://ter.li/jyi8dj.
URL:http://www.pharmajournalist.com/event/leap-td-life-sciences/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251212
DTSTAMP:20260515T020428
CREATED:20250919T115220Z
LAST-MODIFIED:20250919T115220Z
UID:42013-1765238400-1765497599@www.pharmajournalist.com
SUMMARY:2nd ADC Pharmacokinetics & Clinical Pharmacology Summit
DESCRIPTION:With the launch of the FDA’s Project Optimus\, and the evolving clinical pharmacology guidelines for ADCs\, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. \nBringing together a focused audience of clinical pharmacology\, PK\, pharmacometrics\, modelling\, and bioanalysis specialists\, the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit returns to Boston December 9-11\, 2025. \n\nInvestigate non-traditional payloads and bispecific ADCs to understand how unique PK properties influence clinical outcomes with AstraZeneca & Tavotek\nExplore dose optimization and adjustment through modelling and simulation\, with Astellas\nJoin Abbvie & Daiichi Sankyo to use bioanalytical methods to assess structural integrity and DAR for deeper insights into drug clearance\nApply QSP platforms with Novartis to rigorously evaluate the predictive value of computational modelling\nLeverage AI and enhance ADME parameter understanding with Sutro Biopharma & University at Buffalo\n\nSee the event guide: https://ter.li/vrojuh
URL:http://www.pharmajournalist.com/event/2nd-adc-pharmacokinetics-clinical-pharmacology-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251209
DTEND;VALUE=DATE:20251211
DTSTAMP:20260515T020428
CREATED:20251009T103909Z
LAST-MODIFIED:20251009T103909Z
UID:42161-1765238400-1765411199@www.pharmajournalist.com
SUMMARY:7th CNS Drug Delivery Summit
DESCRIPTION:Unlocking Safer\, More Efficient Delivery to Targeted Brain Regions by Advancing Direct\, & Systemic Delivery to the CNS Via TfR1 & Beyond \nDespite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance\, challenges remain in reaching targeted brain regions\, improving predictive modelling\, ensuring efficacy and penetrance\, and developing safer\, targeted delivery approaches. \nJoin 100+ industry experts spanning neuroscientists\, chemists\, device engineers\, conjugation scientists\, DMPK experts\, delivery specialists\, and more at the 7th CNS Drug Delivery Summit to collaborate\, network\, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain. \nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/7th-cns-drug-delivery-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
END:VCALENDAR